Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of GAP-134 Administered Intravenously

NCT00510029

Last updated date
Study Location
Philadelphia, Pennsylvania, 19148, United States
Contact
1-800-718-1021

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Arrhythmia
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-50 years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Generally healthy men and women of nonchildbearing potential (WONCBP), aged 18 to 50 years.

- Body Mass Index (BMI) range of 18 to 30 kg/m2.

- Blood serum creatinine levels less than or equal to the upper limit of normal.

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Any significant cardiovascular, hepatic, renal, respiratory, gastrointestinal,
endocrine, immunologic, dermatologic, hematologic, neurologic, or psychiatric disease.


- Any history of clinically important cardiac arrhythmias and familial history of long
QT syndrome or unexpected cardiac death.


- History of drug and alcohol abuse, positive HIV, HCV, and/or HBs Ag test, and any
clinically important deviation from normal limits in physical examination, vital
signs, 12-lead ECGs, or clinical laboratory test results.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

ArrhythmiaStudy Evaluating GAP-486 on Heart Rhythm in Patients With Coronary Artery Disease
NCT00137332
  1. Sacramento, California
  2. San Francisco, California
  3. Washington, District of Columbia
  4. Orlando, Florida
  5. Peoria, Illinois
  6. Iowa City, Iowa
  7. Worcester, Massachusetts
  8. Ann Arbor, Michigan
  9. Lansing, Michigan
  10. Southfield, Michigan
  11. Minneapolis, Minnesota
  12. Newark, New Jersey
  13. Winston-Salem, North Carolina
  14. Cleveland, Ohio
  15. Cleveland, Ohio
  16. Hershey, Pennsylvania
  17. Wynnewood, Pennsylvania
  18. Falls Church, Virginia
  19. Norfolk, Virginia
  20. Edmonton, Alberta
  21. Vancouver, British Columbia
  22. Victoria, British Columbia
  23. St-Johnâ s, Newfoundland and Labrador
  24. Halifax, Nova Scotia
  25. London, Ontario
  26. Newmarket, Ontario
  27. Toronto, Ontario
  28. Fleurimont, Quebec
  29. Montreal, Quebec
  30. Montreal, Quebec
  31. Montreal, Quebec
  32. Sainte-Foy, Quebec
  33. Sherbrooke, Quebec
ALL GENDERS
18 Years+
years
MULTIPLE SITES
ArrhythmiaSingle Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of GAP-134 Administered Intravenously
NCT00510029
  1. Philadelphia, Pennsylvania
ALL GENDERS
18 Years+
years
MULTIPLE SITES
ArrhythmiaStudy Evaluating GAP-486 in Heart Rhythm
NCT00137293
  1. San Francisco, California
  2. Washington, District of Columbia
  3. Hershey, Pennsylvania
  4. Ottawa, Ontario
  5. Toronto, Ontario
  6. Montreal, Quebec
  7. Montreal, Quebec
ALL GENDERS
18 Years+
years
MULTIPLE SITES
ArrhythmiaAtorvastatin For The Reduction Of Ventricular Arrhythmias
NCT00457340
  1. Aalst,
  2. Antwerpen,
  3. Brugge,
  4. Edegem,
  5. Gent,
  6. Hasselt,
  7. Leuven,
  8. Athens,
  9. Crete,
  10. Rio Patra,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of GAP-134 Administered Intravenously
Official Title  ICMJE Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of GAP-134 Administered Intravenously as a 24-Hour Infusion to Healthy Subjects.
Brief Summary The study will assess the safety, tolerability and pharmacokinetics of single intravenous (IV) doses of GAP-134 in healthy subjects. GAP-134 will be administered as a 24-hour infusion.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Study Design  ICMJE Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Condition  ICMJE Arrhythmia
Intervention  ICMJE Drug: GAP-134
atrial fibrillation 24-hr IV infusion; 1-minute IV bolus; PO
Study Arms  ICMJE GAP-134, IV and Oral
Experimental; Active Comparator; Placebo
Intervention: Drug: GAP-134
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Estimated Enrollment  ICMJE
 (submitted: July 31, 2007)
72
Original Enrollment  ICMJE Same as current
Actual Study Completion Date  ICMJE January 2008
Actual Primary Completion Date January 2008   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria

  • Generally healthy men and women of nonchildbearing potential (WONCBP), aged 18 to 50 years.
  • Body Mass Index (BMI) range of 18 to 30 kg/m2.
  • Blood serum creatinine levels less than or equal to the upper limit of normal.

Exclusion Criteria

  • Any significant cardiovascular, hepatic, renal, respiratory, gastrointestinal, endocrine, immunologic, dermatologic, hematologic, neurologic, or psychiatric disease.
  • Any history of clinically important cardiac arrhythmias and familial history of long QT syndrome or unexpected cardiac death.
  • History of drug and alcohol abuse, positive HIV, HCV, and/or HBs Ag test, and any clinically important deviation from normal limits in physical examination, vital signs, 12-lead ECGs, or clinical laboratory test results.
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years to 50 Years   (Adult)
Accepts Healthy Volunteers  ICMJE Yes
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00510029
Other Study ID Numbers  ICMJE 3205K2-1000
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Wyeth (Registry Contact: Clinical Trial Registry Specialist), Wyeth
Study Sponsor  ICMJE Wyeth is now a wholly owned subsidiary of Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Medical MonitorWyeth is now a wholly owned subsidiary of Pfizer
PRS Account Wyeth is now a wholly owned subsidiary of Pfizer
Verification Date March 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP